Vandria

Vandria is a private, clinical-stage biotechnology company pioneering a novel approach to age-related diseases by targeting mitochondrial dysfunction and inflammation. Its lead asset, VNA-318, is an oral, brain-penetrant small molecule that has completed Phase I studies, showing safety and target engagement for potential use in Alzheimer's disease and other CNS conditions. The company has raised $32M in venture funding from notable investors like ND Capital and Hevolution Foundation and is building a pipeline across CNS, muscle, lung, and liver diseases. With an experienced leadership team and a first-in-class mechanism, Vandria aims to develop disease-modifying therapies for major unmet medical needs.

Platform for discovering first-in-class small molecules that target a novel metabolic pathway to induce mitophagy (clearance of damaged mitochondria) and reduce chronic inflammation, applicable across multiple age-related diseases.

The field of mitophagy and inflammation in aging is emerging but competitive, with several biotechs and large pharma exploring related pathways. In Alzheimer's, Vandria faces intense competition from amyloid, tau, and other neuroinflammation-focused therapies, though its specific mitochondrial target may offer differentiation if clinically validated.